Skip to main content

AstraZeneca and docdok.health improving asthma control

| News

AstraZeneca and docdok.health improving asthma control

12.07.2022

AstraZeneca and the Basel-based startup docdok.health are jointly developing a new digital solution to treat chronic respiratory diseases. Studies at University Hospital Zurich and in Israel should lead to a shift from reactive treatment to early intervention.

The pharmaceutical group AstraZeneca is seeking to improve the treatment of respiratory diseases together with the Basel-based startup docdok.health. Founded in 2017, the company focuses on commercializing software as medical device (SaMD) products for digital therapeutics. It is active across the German-speaking DACH (Germany, Austria and Switzerland) region as well as in Israel.

According to a press release, both companies are striving to develop a digital solution that monitors the asthmatic status of sufferers in real time, recognizes potentially critical situations and immediately sends an alert to the medical staff treating the patient. To achieve this, an app combines feedback from the patients with automatically collected real data, which shows, for example, the air quality in their surroundings.

Using a digital solution, the aim is to expand the basis for assessing the state of health of sick people. As the press release explains, at present this is only based on patient reports on the day that they visit the doctor. This could lead to unsuitable medical measures and improper use of inhalers.

Personalized therapies could help to massively improve the quality of life of more than 550 million people around the world affected by such conditions in addition to relieving the strain on healthcare systems, according to Ohad Goldberg, Country President of AstraZeneca Israel, in the press release. “The ambition of this collaboration is to change the future of the treatment of chronic respiratory diseases”, he states.

The partnership will initially involve a clinical study at Israel’s largest hospital, Sheba Hospital in Tel Aviv, before an observational study at University Hospital Zurich follows. The first phase of the study is set to be concluded by the end of September.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.